logo
Share SHARE
FONT-SIZE Plus   Neg

Nokia Introduces Two New Mobile Phone Models - Quick Facts

Nokia Corp. (NOK) unveiled two new mobile phone models as it continues to speed up its strategy to connect the next billion consumers to information and the internet. The Nokia 110 and Nokia 112 have been designed to appeal to young, urban consumers who want to experience a fast, affordable online experience, the company said.

According to the company, both devices are perfect for communicating across Facebook, Twitter and social media networks. This innovative technology allows users to consume less data by up to 90%, by compressing websites in the cloud. Both devices offer direct access to Facebook and Twitter from their home screens. The Nokia 112 also features preloaded eBuddy instant messaging service right out of the box, so users can use popular chat services to keep conversations going 24/7.

Besides, Nokia 110 and Nokia 112 are both Dual SIM phones, featuring the benefits of Nokia's unique and industry leading Easy Swap technology. This enables users to switch between SIMs quickly without having to remove their battery or turn off their phone. The Easy Swap technology can personalize and remember up to five different SIM cards, giving consumers full control over their costs.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Sony announced Project Field, a new play way to bring card games to life, along with a host of smartphone games at an event in Japan, aiming to accelerate mobile drive. Project Field is a Japan-only card collection platform where actual physical cards will work with a smartphone app. The first title to be announced is based on Yo-kai Watch for mobile. There is no news about an international releas Shares of Credit Suisse Group AG gained around 8 percent in the morning trading in Zurich after the Swiss banking giant raised its group cost savings target, and also confirmed its medium-term 2018 pre-tax income target. It is almost the end of the year. With the exception of a few, many of the biotech stocks, like the following, on which investors had bet big this year have served up only heartbreak. Now, let's take a look at some of the pending clinical trial catalysts of this month, which will make it a December to remember.
comments powered by Disqus
Follow RTT